EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015. Scientific opinion on biotin and contribution to normal energy-yielding metabolism: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Nov 08, 2017
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015.
Scientific opinion on biotin and contribution to normal energy-yielding metabolism:
evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006
Tetens, Inge; EFSA Journal
Link to article, DOI:
10.2903/j.efsa.2015.4181
Publication date:
2015
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA Journal (2015). EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015.
Scientific opinion on biotin and contribution to normal energy-yielding metabolism: evaluation of a health claim
pursuant to Article 14 of Regulation (EC) No 1924/2006. Parma, Italy: Europen Food Safety Authority.  (The
EFSA Journal; No. 4181, Vol. 13(7)). DOI: 10.2903/j.efsa.2015.4181
 SCIENTIFIC OPINION 
ADOPTED: 29 June 2015  PUBLISHED: 17 July 2015 
doi:10.2903/j.efsa.2015.4181  
 
 
www.efsa.europa.eu/efsajournal  EFSA Journal 2015;13(7):4181 
 
 
Biotin and contribution to normal energy-yielding 
metabolism: evaluation of a health claim pursuant to 
Article 14 of Regulation (EC) No 1924/2006 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
 
Abstract 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for 
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the 
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
was asked to deliver an opinion on the scientific substantiation of a health claim related to biotin and 
contribution to normal energy-yielding metabolism. The Panel considers that biotin, the food 
constituent that is the subject of the health claim, is sufficiently characterised. Contribution to normal 
energy-yielding metabolism is a beneficial physiological effect. The Panel has previously assessed a 
claim on biotin and contribution to normal energy-yielding metabolism with a favourable outcome. The 
target population was the general population. The Panel considers that the role of biotin in 
contributing to normal energy-yielding metabolism applies to all ages, including infants and young 
children (from birth to three years). The Panel concludes that a cause and effect relationship has been 
established between the dietary intake of biotin and contribution to normal energy-yielding 
metabolism. The following wording reflects the scientific evidence: ‘Biotin contributes to normal 
energy-yielding metabolism.’ The target population is infants and young children up to three years of 
age. 
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Summary 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for 
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the 
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
was asked to deliver an opinion on the scientific substantiation of a health claim related to biotin and 
contribution to normal energy-yielding metabolism. 
The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
The general approach of the NDA Panel for the evaluation of health claims applications is outlined in 
the EFSA general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health 
claims. 
The food constituent that is the subject of the health claim is biotin, which is an essential nutrient and 
can be measured in foods by established methods. The Panel considers that biotin is sufficiently 
characterised.  
The claimed effect proposed by the applicant is ‘plays an important role in the energy metabolism of 
food’. The target population proposed by the applicant is infants and young children from birth to 
three years of age. The Panel considers that contribution to normal energy-yielding metabolism is a 
beneficial physiological effect. 
The Panel has previously assessed a claim on biotin and contribution to normal energy-yielding 
metabolism with a favourable outcome. The target population was the general population. The Panel 
considered that biotin plays a functional role in energy-yielding metabolism. The Panel considers that 
the role of biotin in contributing to normal energy-yielding metabolism applies to all ages, including 
infants and young children (from birth to three years). 
The Panel concludes that a cause and effect relationship has been established between the dietary 
intake of biotin and contribution to normal energy-yielding metabolism. 
The Panel considers that the following wording reflects the scientific evidence: ‘Biotin contributes to 
normal energy-yielding metabolism.’ 
In order to bear the claim, follow-on formulae should comply with the criteria for the composition of 
follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods for special 
medical purposes intended for use by infants and nutritionally complete foods for special medical 
purposes other than those intended for use by infants should comply with the criteria for the 
composition of these foods as laid down in Directive 1999/21/EC; processed cereal-based foods for 
infants and young children should comply with the criteria for the composition of these foods as laid 
down in Directive 2006/125/EC; and other foodstuffs intended for infants and young children should 
provide at least 15 % of the reference values for the nutritional labelling of foods intended for infants 
and young children as laid down in Directive 2006/141/EC. The target population is infants and young 
children up to three years of age. No Tolerable Upper Intake Level has been established for biotin. 
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1. Introduction  
 Background and Terms of Reference as provided by the requestor 1.1.
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of permitted 
claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA).  
 Interpretation of the Terms of Reference 1.2.
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: biotin and contribution to normal 
energy-yielding metabolism. 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of biotin, a positive assessment of its safety or a decision on whether biotin is, or is not, 
classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework 
of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
 Additional information 1.3.
A claim on biotin and contribution to normal energy-yielding metabolism has previously been assessed 
by the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) with a favourable 
outcome (EFSA NDA Panel, 2009). 
2. Data and Methodologies  
 Data 2.1.
2.1.1. Information provided by the applicant 
Food/constituent as stated by the applicant: 
 According to the applicant, the food constituent for which the claim is made is vitamin B7 
(biotin). 
Health relationship as claimed by the applicant: 
 According to the applicant, vitamin B7 plays an important role in the energy metabolism of 
food. 
                                                          
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health 
claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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Wording of the health claim as proposed by the applicant: 
 The applicant has proposed the following wording for the health claim: ‘Vitamin B7 (biotin) 
contributes to normal fat metabolism and energy production’. As equivalent alternative 
wordings, the applicant has also proposed: ‘Vitamin B7 (biotin) is needed to release energy 
from food’; ‘Vitamin B7 (biotin) is important for the fat metabolism’; and ‘Vitamin B7 (biotin) 
helps release energy from fats’. 
Specific conditions of use as proposed by the applicant: 
 The target population proposed by the applicant is infants and young children from birth to 
three years of age. 
 According to the applicant, the quantities needed to achieve the claimed effect are as follows: 
– For follow-on formulae, the content of vitamin B7 should be within the range set in 
Directive 2006/141/EC. 
– For Foods for Special Medical Purpose for infants and young children, the content of 
vitamin B7 should be within the range set in Directive 1999/21/EC, unless that is contrary 
to the intended use of the product. 
– For processed cereal-based foods and baby foods and for the other foods intended for 
infants and young children, the content of vitamin B7 should reach at least 15 % of the 
Nutrient Reference Values set in Directive 2006/141/EC, i.e. 15 % of 10 µg (1.5 µg) per 
100 g or 100 mL serving, as reconstituted. 
2.1.2. Data provided by the applicant 
The applicant provided a health claim application on biotin and contribution to normal energy-yielding 
metabolism pursuant to Article 14 of Regulation 1924/2006. The application was presented in a 
common and structured format as outlined in the scientific and technical guidance for the preparation 
and presentation of applications for authorisation of health claims (EFSA NDA Panel, 2011a). 
As outlined in the EFSA general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 
14 health claims (EFSA NDA Panel, 2011b), it is the responsibility of the applicant to provide the 
totality of the available evidence. 
 Methodologies 2.2.
The general approach of the NDA Panel for the evaluation of health claims applications is outlined in 
the EFSA general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health 
claims (EFSA NDA Panel, 2011b). 
3. Assessment 
 Characterisation of the food/constituent 3.1.
The food constituent that is the subject of the health claims is biotin, which is an essential nutrient 
and can be measured in foods by established methods.  
Biotin occurs naturally in foods as free biotin and in protein-bound forms; there are eight 
stereoisomers, but the D(+)-biotin is the only naturally occurring isomer that plays a role in human 
metabolism, and currently the only form authorised for addition to foods (Annex II of Regulation (EC) 
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No 1925/2006,2 Annex II of Directive 2002/46/EC,3 Annex III of Directive 2006/141/EC,4 Annex IV of 
Directive 2006/125/EC,5 and Directive 2001/15/EC6). 
This evaluation applies to biotin naturally present in foods and those forms authorised for addition to 
foods (Annex II of Regulation (EC) No 1925/2006, Annex II of Directive 2002/46/EC, Annex III of 
Directive 2006/141/EC, Annex IV of Directive 2006/125/EC, and Directive 2001/15/EC). 
The Panel considers that the food constituent, biotin, which is the subject of the health claim, is 
sufficiently characterised. 
 Relevance of the claimed effect to human health 3.2.
The claimed effect proposed by the applicant is ‘plays an important role in the energy metabolism of 
food’. The target population proposed by the applicant is infants and young children from birth to 
three years of age. 
The Panel considers that contribution to normal energy-yielding metabolism is a beneficial 
physiological effect. 
 Scientific substantiation of the claimed effect 3.3.
The Panel has previously assessed a claim on biotin and contribution to normal energy-yielding 
metabolism with a favourable outcome (EFSA NDA Panel, 2009). The target population was the 
general population.  
The Panel considered that biotin plays a functional role in energy-yielding metabolism (EFSA NDA 
Panel, 2009). 
The Panel considers that the role of biotin in contributing to normal energy-yielding metabolism 
applies to all ages, including infants and young children (from birth to three years). 
The Panel concludes that a cause and effect relationship has been established between the dietary 
intake of biotin and contribution to normal energy-yielding metabolism. 
 Panel’s comments on the proposed wording 3.4.
The Panel considers that the following wording reflects the scientific evidence: ‘Biotin contributes to 
normal energy-yielding metabolism.’  
 Conditions and restrictions of use 3.5.
The Panel considers that in order to bear the claim: 
 follow-on formulae should comply with the criteria for the composition of follow-on formulae 
as laid down in Directive 2006/141/EC; 
 nutritionally complete foods for special medical purposes intended for use by infants and 
nutritionally complete foods for special medical purposes other than those intended for use by 
infants should comply with the criteria for the composition of these foods as laid down in 
Directive 1999/21/EC; 
 processed cereal-based foods for infants and young children should comply with the criteria 
for the composition of these foods as laid down in Directive 2006/125/EC; 
                                                          
2 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
3 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the 
Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
4 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 
1999/21/EC Text with EEA relevance. OJ L 401, 30.12.2006, p. 1–33.  
5 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and 
young children. OJ L 339, 6.12.2006, p. 16–35. 
6 Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for specific nutritional purposes in 
foods for particular nutritional uses. OJ L 52, 22.2.2001, p. 19–25.  
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 other foodstuffs intended for infants and young children should provide at least 15 % of the 
reference values for the nutritional labelling of foods intended for infants and young children 
as laid down in Directive 2006/141/EC. 
Such amounts can be easily consumed as part of a balanced diet. The target population is infants and 
young children up to three years of age. No Tolerable Upper Intake Level has been established for 
biotin (SCF, 2001).  
4. Conclusions 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, biotin, which is the subject of the health claim, is sufficiently 
characterised.  
 The claimed effect proposed by the applicant is ‘plays an important role in the energy 
metabolism of food’. The target population proposed by the applicant is infants and young 
children from birth to three years of age. Contribution to normal energy-yielding metabolism 
is a beneficial physiological effect. 
 A cause and effect relationship has been established between the consumption of the dietary 
intake of biotin and contribution to normal energy-yielding metabolism. 
 The following wording reflects the scientific evidence: ‘Biotin contributes to normal energy-
yielding metabolism.’ 
 In order to bear the claim, follow-on formulae should comply with the criteria for the 
composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally 
complete foods for special medical purposes intended for use by infants and nutritionally 
complete foods for special medical purposes other than those intended for use by infants 
should comply with the criteria for the composition of these foods as laid down in Directive 
1999/21/EC; processed cereal-based foods for infants and young children should comply with 
the criteria for the composition of these foods as laid down in Directive 2006/125/EC; other 
foodstuffs intended for infants and young children should provide at least 15 % of the 
reference values for the nutritional labelling of foods intended for infants and young children 
as laid down in Directive 2006/141/EC. The target population is infants and young children up 
to three years of age. No Tolerable Upper Intake Level has been established for biotin (SCF, 
2001). 
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Documentation provided to EFSA 
1. Health claim application on ‘vitamin B7 (biotin) plays an important role in the energy metabolism 
of food’ pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 0108_FR). 
Submitted by Specialised Nutrition Europe (formerly IDACE), 31 Avenue des Nerviens, 1040 
Brussels, Belgium. 
2. This application was received by EFSA on 14 February 2008. 
3. The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
4. On 26 March 2008, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
5. On 29 April 2015, EFSA received the missing information as submitted by the applicant. 
6. The scientific evaluation procedure started on 3 June 2015. 
7. During its meeting on 29 June 2015, the NDA Panel, having evaluated the data, adopted an 
opinion on the scientific substantiation of a health claim related  biotin and contribution to 
normal energy-yielding metabolism. 
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